• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

镓-前列腺特异性膜抗原正电子发射断层显像/计算机断层扫描:欧洲核医学协会和美国核医学与分子影像学会联合发布的前列腺癌成像程序指南:第1.0版

Ga-PSMA PET/CT: Joint EANM and SNMMI procedure guideline for prostate cancer imaging: version 1.0.

作者信息

Fendler Wolfgang P, Eiber Matthias, Beheshti Mohsen, Bomanji Jamshed, Ceci Francesco, Cho Steven, Giesel Frederik, Haberkorn Uwe, Hope Thomas A, Kopka Klaus, Krause Bernd J, Mottaghy Felix M, Schöder Heiko, Sunderland John, Wan Simon, Wester Hans-Jürgen, Fanti Stefano, Herrmann Ken

机构信息

Department of Molecular and Medical Pharmacology, David Geffen School of Medicine, UCLA, 10833 Le Conte Ave, 200 Medical Plaza, Los Angeles, CA, USA.

Department of Nuclear Medicine, Ludwig-Maximilians-University of Munich, Munich, Germany.

出版信息

Eur J Nucl Med Mol Imaging. 2017 Jun;44(6):1014-1024. doi: 10.1007/s00259-017-3670-z.

DOI:10.1007/s00259-017-3670-z
PMID:
28283702
Abstract

The aim of this guideline is to provide standards for the recommendation, performance, interpretation and reporting of Ga-PSMA PET/CT for prostate cancer imaging. These recommendations will help to improve accuracy, precision, and repeatability of Ga-PSMA PET/CT for prostate cancer essentially needed for implementation of this modality in science and routine clinical practice.

摘要

本指南的目的是为镓-PSMA PET/CT用于前列腺癌成像的推荐、实施、解读及报告提供标准。这些推荐将有助于提高镓-PSMA PET/CT在前列腺癌成像方面的准确性、精确性和可重复性,这对于在科学研究和日常临床实践中应用该模式至关重要。

相似文献

1
Ga-PSMA PET/CT: Joint EANM and SNMMI procedure guideline for prostate cancer imaging: version 1.0.镓-前列腺特异性膜抗原正电子发射断层显像/计算机断层扫描:欧洲核医学协会和美国核医学与分子影像学会联合发布的前列腺癌成像程序指南:第1.0版
Eur J Nucl Med Mol Imaging. 2017 Jun;44(6):1014-1024. doi: 10.1007/s00259-017-3670-z.
2
Ga-Labeled Prostate-specific Membrane Antigen Ligand Positron Emission Tomography/Computed Tomography for Prostate Cancer: A Systematic Review and Meta-analysis.Ga 标记前列腺特异性膜抗原配体正电子发射断层扫描/计算机断层扫描在前列腺癌中的应用:系统评价和荟萃分析。
Eur Urol Focus. 2018 Sep;4(5):686-693. doi: 10.1016/j.euf.2016.11.002. Epub 2016 Nov 15.
3
PSMA PET/CT: joint EANM procedure guideline/SNMMI procedure standard for prostate cancer imaging 2.0.PSMA PET/CT:前列腺癌成像 2.0 的 EANM 程序指南/ SNMMI 程序标准联合。
Eur J Nucl Med Mol Imaging. 2023 Apr;50(5):1466-1486. doi: 10.1007/s00259-022-06089-w. Epub 2023 Jan 5.
4
[F]Fluciclovine PET/CT: joint EANM and SNMMI procedure guideline for prostate cancer imaging-version 1.0.[F]氟代脱氧胸苷正电子发射断层扫描/计算机断层扫描:欧洲核医学与分子影像学会和美国核医学与分子影像学会联合制定的前列腺癌成像程序指南 - 第1.0版
Eur J Nucl Med Mol Imaging. 2020 Mar;47(3):579-591. doi: 10.1007/s00259-019-04614-y. Epub 2019 Dec 11.
5
A prospective randomized multicentre study of the impact of gallium-68 prostate-specific membrane antigen (PSMA) PET/CT imaging for staging high-risk prostate cancer prior to curative-intent surgery or radiotherapy (proPSMA study): clinical trial protocol.一项前瞻性随机多中心研究,评估镓-68 前列腺特异性膜抗原(PSMA)PET/CT 成像在根治性手术或放疗前对高危前列腺癌分期的影响(proPSMA 研究):临床试验方案。
BJU Int. 2018 Nov;122(5):783-793. doi: 10.1111/bju.14374. Epub 2018 Jun 3.
6
Cold Kit for Prostate-Specific Membrane Antigen (PSMA) PET Imaging: Phase 1 Study of Ga-Tris(Hydroxypyridinone)-PSMA PET/CT in Patients with Prostate Cancer.前列腺特异性膜抗原 (PSMA) PET 成像用冷试剂盒:Ga-Tris(羟基亚乙基二膦酸)-PSMA PET/CT 用于前列腺癌患者的 1 期研究。
J Nucl Med. 2018 Apr;59(4):625-631. doi: 10.2967/jnumed.117.199554. Epub 2017 Oct 6.
7
More advantages in detecting bone and soft tissue metastases from prostate cancer using F-PSMA PET/CT.使用F-PSMA PET/CT检测前列腺癌骨和软组织转移方面有更多优势。
Hell J Nucl Med. 2019 Jan-Apr;22(1):6-9. doi: 10.1967/s002449910952. Epub 2019 Mar 7.
8
Gallium-68 Prostate-Specific Membrane Antigen PET Imaging.镓-68前列腺特异性膜抗原正电子发射断层显像
PET Clin. 2017 Apr;12(2):219-234. doi: 10.1016/j.cpet.2016.12.004. Epub 2017 Feb 1.
9
An F-Labeled PSMA Ligand for PET/CT of Prostate Cancer: First-in-Humans Observational Study and Clinical Experience with F-JK-PSMA-7 During the First Year of Application.一种 F 型 PSMA 配体用于前列腺癌的 PET/CT:F-JK-PSMA-7 在应用的第一年中的首例人体观察性研究和临床经验。
J Nucl Med. 2020 Feb;61(2):202-209. doi: 10.2967/jnumed.119.229542. Epub 2019 Jul 19.
10
PSMA PET and Radionuclide Therapy in Prostate Cancer.前列腺癌中的前列腺特异性膜抗原正电子发射断层扫描与放射性核素治疗
Semin Nucl Med. 2016 Nov;46(6):522-535. doi: 10.1053/j.semnuclmed.2016.07.006. Epub 2016 Sep 3.

引用本文的文献

1
A Systematic Review of Multimodal Deep Learning and Machine Learning Fusion Techniques for Prostate Cancer Classification.前列腺癌分类的多模态深度学习与机器学习融合技术的系统综述
medRxiv. 2025 Aug 11:2025.08.07.25333235. doi: 10.1101/2025.08.07.25333235.
2
Ga Extemporaneous Preparations in Radiopharmacy.放射性药物学中的镓临时制剂。
Pharmaceutics. 2025 Jun 20;17(7):802. doi: 10.3390/pharmaceutics17070802.
3
Interpretation of PSMA-PET Among Urologists: A Prospective Multicentric Evaluation.泌尿外科医生对前列腺特异性膜抗原正电子发射断层扫描(PSMA-PET)的解读:一项前瞻性多中心评估。

本文引用的文献

1
68Ga-PSMA-11 PET Represents the Tumoricidal Effect of 223Ra in a Patient With Castrate-Resistant Metastatic Prostate Cancer.68Ga-PSMA-11 PET 显示镭-223 治疗去势抵抗性转移性前列腺癌的肿瘤杀伤效应。
Clin Nucl Med. 2016 Sep;41(9):695-6. doi: 10.1097/RLU.0000000000001286.
2
Sensitivity, Specificity, and Predictors of Positive Ga-Prostate-specific Membrane Antigen Positron Emission Tomography in Advanced Prostate Cancer: A Systematic Review and Meta-analysis.前列腺特异性膜抗原正电子发射断层扫描在晚期前列腺癌中的敏感性、特异性和阳性预测值:系统评价和荟萃分析。
Eur Urol. 2016 Dec;70(6):926-937. doi: 10.1016/j.eururo.2016.06.021. Epub 2016 Jun 28.
3
Cancers (Basel). 2025 Jun 24;17(13):2122. doi: 10.3390/cancers17132122.
4
Pharmacokinetics and dosimetry of [Lu]Lu-PSMA-617 and [Ga]Ga-PSMA-11 in Japanese patients with PSMA-positive mCRPC.[镥]镥-PSMA-617和[镓]镓-PSMA-11在日本PSMA阳性转移性去势抵抗性前列腺癌患者中的药代动力学和剂量学
Ann Nucl Med. 2025 Jul 10. doi: 10.1007/s12149-025-02079-8.
5
An Evaluation of the Diagnostic Accuracy of [68Ga]Ga-PSMA-11 vs. [18F]F-PSMA-1007 PET/CT for Lymph Node Staging in Patient Candidates for Radical Prostatectomy and Lymph Node Dissection: A Single Institutional Analysis.[68Ga]镓-PSMA-11与[18F]氟-PSMA-1007 PET/CT在前列腺癌根治术和淋巴结清扫术候选患者淋巴结分期诊断准确性的评估:单机构分析
Diagnostics (Basel). 2025 Jun 12;15(12):1492. doi: 10.3390/diagnostics15121492.
6
Therapeutic Consequences of Ga-PSMA-11-PET/CT in Prostate Cancer in Correlation to the Gleason Score, PSA Value, and D'Amico-Defined Risk Groups.镓-PSMA-11-PET/CT在前列腺癌中的治疗效果与 Gleason 评分、PSA 值及达米科定义的风险组的相关性
Cancers (Basel). 2025 Jun 11;17(12):1944. doi: 10.3390/cancers17121944.
7
Current Status and Future Perspectives of Nuclear Medicine in Prostate Cancer from Imaging to Therapy: A Comprehensive Review.从成像到治疗的前列腺癌核医学现状与未来展望:综述
Biomedicines. 2025 May 7;13(5):1132. doi: 10.3390/biomedicines13051132.
8
The potential of gallium-68 prostate-specific membrane antigen positron emission tomography/computed tomography as a main diagnostic tool in prostate cancer staging.镓-68前列腺特异性膜抗原正电子发射断层扫描/计算机断层扫描作为前列腺癌分期主要诊断工具的潜力。
Cent European J Urol. 2025;78(1):52-60. doi: 10.5173/ceju.2025.0014. Epub 2025 Mar 14.
9
Head-to-head comparison of Ga-PSMA-11 and F-FDG in delayed PET/CT imaging in prostate cancer diagnosis.镓-PSMA-11与氟代脱氧葡萄糖在前列腺癌诊断的延迟PET/CT成像中的直接比较。
Front Oncol. 2025 Apr 11;15:1515653. doi: 10.3389/fonc.2025.1515653. eCollection 2025.
10
Ga-labeled prostate specific membrane antigen HBED-CC PET/MRI for staging and evaluating the clinicopathological characteristics in newly diagnosed prostate cancer.镓标记的前列腺特异性膜抗原HBED-CC PET/MRI用于新诊断前列腺癌的分期及评估临床病理特征
Eur J Med Res. 2025 Apr 21;30(1):311. doi: 10.1186/s40001-025-02567-7.
Comparison of bone scintigraphy and Ga-PSMA PET for skeletal staging in prostate cancer.
骨闪烁显像与镓-PSMA PET在前列腺癌骨骼分期中的比较
Eur J Nucl Med Mol Imaging. 2016 Nov;43(12):2114-2121. doi: 10.1007/s00259-016-3435-0. Epub 2016 Jun 12.
4
(68)Ga-PSMA ligand PET/CT in patients with prostate cancer: How we review and report.前列腺癌患者的(68)Ga-PSMA配体PET/CT:我们的评估与报告方式
Cancer Imaging. 2016 Jun 8;16(1):14. doi: 10.1186/s40644-016-0072-6.
5
Radiation dosimetry of (68)Ga-PSMA-11 (HBED-CC) and preliminary evaluation of optimal imaging timing.(68)Ga-PSMA-11(HBED-CC)的辐射剂量测定及最佳成像时间的初步评估。
Eur J Nucl Med Mol Imaging. 2016 Aug;43(9):1611-20. doi: 10.1007/s00259-016-3419-0. Epub 2016 Jun 3.
6
Biodistribution and radiation dosimetry of (68)Ga-PSMA HBED CC-a PSMA specific probe for PET imaging of prostate cancer.(68)镓标记的前列腺特异性膜抗原(PSMA)-六氮杂环十二烷四乙酸(HBED-CC)——一种用于前列腺癌PET成像的PSMA特异性探针的生物分布及辐射剂量测定
Eur J Nucl Med Mol Imaging. 2016 Oct;43(11):1962-70. doi: 10.1007/s00259-016-3424-3. Epub 2016 May 20.
7
Response and Tolerability of a Single Dose of 177Lu-PSMA-617 in Patients with Metastatic Castration-Resistant Prostate Cancer: A Multicenter Retrospective Analysis.单剂量177Lu-PSMA-617治疗转移性去势抵抗性前列腺癌患者的疗效与耐受性:一项多中心回顾性分析
J Nucl Med. 2016 Sep;57(9):1334-8. doi: 10.2967/jnumed.116.173757. Epub 2016 Apr 7.
8
Diagnostic potential of PET/CT using a Ga-labelled prostate-specific membrane antigen ligand in whole-body staging of renal cell carcinoma: initial experience.使用镓标记的前列腺特异性膜抗原配体的PET/CT在肾细胞癌全身分期中的诊断潜力:初步经验
Eur J Nucl Med Mol Imaging. 2017 Jan;44(1):102-107. doi: 10.1007/s00259-016-3360-2. Epub 2016 Mar 21.
9
Intra-individual comparison of (68)Ga-PSMA-11-PET/CT and multi-parametric MR for imaging of primary prostate cancer.(68)镓-PSMA-11正电子发射断层扫描/计算机断层扫描(PET/CT)与多参数磁共振成像用于原发性前列腺癌成像的个体内比较
Eur J Nucl Med Mol Imaging. 2016 Jul;43(8):1400-6. doi: 10.1007/s00259-016-3346-0. Epub 2016 Mar 14.
10
Systemic Radioligand Therapy with (177)Lu Labeled Prostate Specific Membrane Antigen Ligand for Imaging and Therapy in Patients with Metastatic Castration Resistant Prostate Cancer.放射性配体疗法联合(177)Lu 标记的前列腺特异性膜抗原配体在转移性去势抵抗性前列腺癌患者的成像和治疗中的应用。
J Urol. 2016 Aug;196(2):382-91. doi: 10.1016/j.juro.2016.02.2969. Epub 2016 Mar 8.